medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-138-143medsovet-5308Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONКлинический пример длительного контроля диссеминированного перстневидноклеточного рака желудка на фоне химиотерапии второй линии лечения в комбинации с бевацизумабомClinical example of long-term control of disseminated signet-ring cell carcinoma of the stomach against the background of chemotherapy of the second line of treatment in combination with bevacizumabhttps://orcid.org/0000-0002-5039-6360ТитоваТ. А.TitovaT. A.

врач-онколог онкологического отделения лекарственных методов лечения (химиотерапевтического) №1 Научно-исследовательского института клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова

115478, Россия, Москва, Каширское шоссе, д. 24

Oncologist at the Oncology Department of Medicinal Methods of Treatment (Chemotherapy) No. 1 of the Scientific ResearchInstitute of Clinical Oncology named after Academician of RAS and RAMS N.N. Trapeznikov

24, Kashirskoye sh., 115478, Moscow, Russia

tatiana.titovadoc@gmail.comhttps://orcid.org/0000-0002-1693-0523БесоваН. С.BesovaN. S.

к.м.н., старший научный сотрудник онкологического отделения лекарственных методов лечения (химиотерапевтического) №1 Научно-исследовательского института клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова

115478, Россия, Москва, Каширское шоссе, д. 24 

Cand. of Sci. (Med), Senior Researcher at the Oncology Department of Medicinal Methods of Treatment (Chemotherapy) No. 1 of the Scientific Research Institute of Clinical Oncology named after Academician of RAS and RAMS N.N. Trapeznikov

24, Kashirskoye sh., 115478, Moscow, Russia

besovans@mail.ruhttps://orcid.org/0000-0002-8936-3590АртамоноваЕ. В.ArtamonovaE. V.

д.м.н., заведующая онкологическим отделением лекарственных методов лечения (химиотерапевтического) №1 Научно-исследовательского института клинической онкологии имени академика РАН и РАМН Н.Н. Трапезникова

115478, Россия, Москва, Каширское шоссе, д. 24 

Dr. of Sci. (Med), Head of the Oncology Department of Medicinal Methods of Treatment (Chemotherapy) No. 1 of the Scientific Research Institute of Clinical Oncology named after Academician of RAS and RAMS N.N. Trapeznikov

24, Kashirskoye sh., 115478, Moscow, Russia

artamonovaE@mail.ruНациональный медицинский исследовательский центр онкологии имени Н.Н. БлохинаРоссияFederal State Budgetary Institution «N.N.Blokhin Russian Cancer Research Centre» of the Ministry of Health of Russian FederationRussian Federation201907122019019138143Copyright © Титова Т.А., Бесова Н.С., Артамонова Е.В., 20192019Титова Т.А., Бесова Н.С., Артамонова Е.В.Titova T.A., Besova N.S., Artamonova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5308рак желудкабевацизумабвторая линия терапииstomach cancerbevacizumabsecond line of therapyReferencesBray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clincians. 2018;68(6):394–424. doi: 10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clincians. 2018;68(6):394–424. doi: 10.3322/caac.21492.Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). Cancer statistics in Russia in 2017. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2018. (In Russ.) Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.Li T., Kang G., Wang T., Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687-702. doi: 10.3892/ol.2018.8733.Li T., Kang G., Wang T., Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687-702. doi: 10.3892/ol.2018.8733.Wang L., Chang Y., Xu J., Zhang Q. Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. Biomed Res Int. 2016;2016:8103019. doi: 10.1155/2016/8103019.Wang L., Chang Y., Xu J., Zhang Q. Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients. Biomed Res Int. 2016;2016:8103019. doi: 10.1155/2016/8103019.Scartozzi M., Giampieri R., Loretelli C., Bittoni A., Mandolesi A., Faloppi L. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancerpatients. Pharmacogenomics. 2013;14(16):1991-1998. doi: 10.2217/pgs.13.185.Scartozzi M., Giampieri R., Loretelli C., Bittoni A., Mandolesi A., Faloppi L. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancerpatients. Pharmacogenomics. 2013;14(16):1991-1998. doi: 10.2217/pgs.13.185.Lv Y., Song L., Chang L., Zhang X., Liu Y., Liu W. Effect of bevacizumab combined with chemotherapy at different sequences in the gastriccancer-bearing nude mice. J Cancer Res Ther. 2018;14(8):190-196. doi: 10.4103/0973-1482.171364.Lv Y., Song L., Chang L., Zhang X., Liu Y., Liu W. Effect of bevacizumab combined with chemotherapy at different sequences in the gastriccancer-bearing nude mice. J Cancer Res Ther. 2018;14(8):190-196. doi: 10.4103/0973-1482.171364.Ohtsu A., Shah M..A, Van Cutsem E., Rha S.Y., Sawaki A., Park S.R. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. Journal of Clinical Oncology. 2011;29(30):3968–3976. DoI: 10.1200/JCO.2011.36.2236.Ohtsu A., Shah M..A, Van Cutsem E., Rha S.Y., Sawaki A., Park S.R. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, doubleblind, placebo-controlled phase III study. Journal of Clinical Oncology. 2011;29(30):3968–3976. DoI: 10.1200/JCO.2011.36.2236.Shen L., Li J., Xu J., Pan H., Dai G., Qin S., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168–176. doi: 10.1007/s10120-014-0351-5.Shen L., Li J., Xu J., Pan H., Dai G., Qin S., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18(1):168–176. doi: 10.1007/s10120-014-0351-5.Fuchs C.S., Shitara K., Di Bartolomeo M. et al.; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5.Fuchs C.S., Shitara K., Di Bartolomeo M. et al.; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 2019;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5.Van Cutsem E., de Haas S., Kang Y.K., Ohtsu A., et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. J Clin Oncol. 2012;30(17):2119-2127. doi: 10.1200/JCO.2011.39.9824.Van Cutsem E., de Haas S., Kang Y.K., Ohtsu A., et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. J Clin Oncol. 2012;30(17):2119-2127. doi: 10.1200/JCO.2011.39.9824.Scartozzi M., Loretelli C., Galizia E., Mandolesi A., Pistelli M., Bittoni A., et al. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One. 2012;7(7):e38192. doi: 10.1371/journal.pone.0038192.Scartozzi M., Loretelli C., Galizia E., Mandolesi A., Pistelli M., Bittoni A., et al. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One. 2012;7(7):e38192. doi: 10.1371/journal.pone.0038192.Li J., Qin S., Xu J., Guo W., Xiong J., Bai Y., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology. 2013; 1 26):3219–3225. doi: 10.1200/JCO.2013.48.8585.Li J., Qin S., Xu J., Guo W., Xiong J., Bai Y., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology. 2013; 1 26):3219–3225. doi: 10.1200/JCO.2013.48.8585.Liu L., Ma X.L., Xiao Z.L., Li M., Cheng S.H., Wei Y.Q. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer. 2012;13(7):3089-3097. doi: 10.7314/apjcp.2012.13.7.3089.Liu L., Ma X.L., Xiao Z.L., Li M., Cheng S.H., Wei Y.Q. Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer. 2012;13(7):3089-3097. doi: 10.7314/apjcp.2012.13.7.3089.Enzinger P.C., Fidias P., Meyerhardt J., et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Poster A68 presented at the ASCO Gastrointestinal Cancers Symposium; San Francisco, CA. January 26-28, 2006.Enzinger P.C., Fidias P., Meyerhardt J., et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Poster A68 presented at the ASCO Gastrointestinal Cancers Symposium; San Francisco, CA. January 26-28, 2006.Yang L., Jiang X., Yan H., Li Y., Zhen H., Chang B., Kariminia S., Li Q. Irinotecan-containing doublet treatmentversus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. doi: 10.1186/s12876-018-0772-4.Yang L., Jiang X., Yan H., Li Y., Zhen H., Chang B., Kariminia S., Li Q. Irinotecan-containing doublet treatmentversus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. doi: 10.1186/s12876-018-0772-4.

The authors declare that there are no conflicts of interest present.